Latest news with #Euronext
Business Wire
2 days ago
- Health
- Business Wire
Poxel SA: New Scientific Presentations by Key Opinion Leaders to Further Highlight the Therapeutic Potential of Imeglimin at ADA 2025, the Leading Diabetes Conference
LYON, France--(BUSINESS WIRE)--Regulatory News: POXEL SA (Euronext : POXEL - FR0012432516), a clinical stage biopharmaceutical company developing innovative treatments for chronic serious diseases with metabolic pathophysiology, including Metabolic dysfunction-Associated SteatoHepatitis (MASH) and rare metabolic disorders, today announces that five presentations in relation to the potential of Imeglimin, marketed under the brand name TWYMEEG ® in Japan, will be made at the 85 th Scientific Sessions of the American Diabetes Associations, from June 20 to 23, 2025, in Chicago, Illinois (U.S.A). A total of 5 publications, including results from 2 clinical trials and 3 non-clinical studies supported by Sumitomo Pharma, will be delivered by leading Japanese diabetes experts. Main topics include: Potential of Imeglimin to Improve Inflammation and Fibrosis in Diabetic Kidney Disease, by Yoshimi Muta, from Fukuoka University (Fukuoka, Japan) The Efficacy of Imeglimin and Metformin on Insulin Sensitivity and Secretion Using Oral Minimal Model, by Ryota Usui, from Kansai Electric Power Hospital (Osaka, Japan) Attempts to Identify Predictors of Glycemic Control with Imeglimin—Machine Learning Analysis Using Clinical Trial Data, by Katsuhiko Hagi, from Sumitomo Pharma Therapeutic Potential of Imeglimin for Diabetic Neuropathy—Neuroprotective Effects in Type 1 Diabetic Rats, by Wataru Nihei, from the Aichi Gakuin University School of Pharmacy's Laboratory of Medicine (Nagoya, Japan) Effect of Imeglimin on Periodontitis in Streptozotocin-Induced Diabetic Rats, by Shun Kondo, from the Aichi Gakuin University's School of Dentistry (Nagoya, Japan) Thomas Kuhn, CEO of Poxel, stated: 'We are very pleased to see that the potential of Imeglimin (TWYMEEG ®) in the fight against type 2 diabetes and its associated conditions continues to generate enthusiasm within the scientific community, with the support of our partner Sumitomo Pharma. The presentations on TWYMEEG ®, at the world's most important academic event on diabetes provide further confirmation of its value as a treatment for diabetic patients.' About Poxel SA Poxel is a clinical stage biopharmaceutical company developing innovative treatments for chronic serious diseases with metabolic pathophysiology, including metabolic dysfunction-associated steatohepatitis (MASH) and rare disorders. For the treatment of MASH, PXL065 (deuterium-stabilized R -pioglitazone) met its primary endpoint in a streamlined Phase 2 trial (DESTINY-1). In rare diseases, development of PXL770, a first-in-class direct adenosine monophosphate-activated protein kinase (AMPK) activator, is focused on the treatment of adrenoleukodystrophy (ALD) and autosomal dominant polycystic kidney disease (ADPKD). TWYMEEG ® (Imeglimin), Poxel's first-in-class product that targets mitochondrial dysfunction, is now marketed for the treatment of type 2 diabetes in Japan by Sumitomo Pharma and Poxel expects to receive royalties and sales-based payments. Poxel has a strategic partnership with Sumitomo Pharma for Imeglimin in Japan. Listed on Euronext Paris, Poxel is headquartered in Lyon, France, and has subsidiaries in Boston, MA, and Tokyo, Japan. For more information, please visit: All statements other than statements of historical fact included in this press release about future events are subject to (i) change without notice and (ii) factors beyond the Company's control. These statements may include, without limitation, any statements preceded by, followed by or including words such as 'target,' 'believe,' 'expect,' 'aim,' 'intend,' 'may,' 'anticipate,' 'estimate,' 'plan,' 'project,' 'will,' 'can have,' 'likely,' 'should,' 'would,' 'could' and other words and terms of similar meaning or the negative thereof. Forward-looking statements are subject to inherent risks and uncertainties beyond the Company's control that could cause the Company's actual results or performance to be materially different from the expected results or performance expressed or implied by such forward-looking statements. The Company does not endorse or is not otherwise responsible for the content of external hyperlinks referred to in this press release.
Fashion Value Chain
3 days ago
- Business
- Fashion Value Chain
Signify and Madhya Pradesh Tourism Board Partner to Illuminate 61 Villages, Empowering Local Communities Under ‘Har Gaon Roshan' CSR Initiative
Signify, the world leader in lighting, today announced a collaboration with the Madhya Pradesh Tourism Board to bring sustainable outdoor lighting infrastructure to 61 tourism-led villages across the state under its 'Har Gaon Roshan' CSR Program. This initiative prioritizes tribal communities and regions near national parks, aiming to enhance safety, visibility, and the overall tourist experience in these underserved areas. Signify and Madhya Pradesh Tourism Board Partner to Illuminate 61 Villages The project will be implemented in partnership with Signify's long-standing NGO partner, Haritika, providing energy efficient outdoor lighting solutions in these remote villages. By supporting local infrastructure development, the project will also enable in creating a well-lit environment for tourists and locals, while fostering economic opportunities for the communities. The official Memorandum of Understanding (MoU) was exchanged at a formal event in Bhopal, graced by the Hon'ble Chief Minister of Madhya Pradesh, Shri Mohan Yadav, and Signify's leadership, highlighting Signify's commitment to sustainable development and community empowerment through innovative lighting solutions. Commenting on the partnership, Nikhil Gupta, Head of Marketing, Strategy, Govt Affairs, and CSR, Signify Greater India said, 'At Signify, we believe in bringing the best of innovations to the communities across India, through our Har Gaon Roshan CSR initiative. For this project, we are thankful to the support of Madhya Pradesh tourism board for aiding our collective mission to strengthen rural communities through tourism. By illuminating these villages, we are enhancing the safety and visibility of these areas. This partnership reflects our commitment to using light to positively impact lives in the most underserved regions of India, fostering sustainable growth and community empowerment.' Madhya Pradesh Tourism Board representative added, 'This partnership with Signify marks a significant step toward realizing our collective vision of transforming rural tourism in Madhya Pradesh. Providing lighting to these villages will not only improve safety and infrastructure but also unlock new avenues for community-based tourism, economic development and enhance livelihood activities especially during evening hours such as showcasing local artifacts, promoting handloom and handicraft work, selling local produce such as spices and organic goods, and organizing cultural performances and evening village tours. ' About Signify Signify (Euronext: LIGHT) is the world leader in lighting for professionals, consumers and the Internet of Things. Our Philips products, Interact systems and data-enabled services deliver business value and transform life in homes, buildings and public spaces. In 2024, we had sales of EUR 6.1 billion, approximately 29,000 employees and a presence in over 70 countries. We unlock the extraordinary potential of light for brighter lives and a better world. We have been in the Dow Jones Sustainability World Index since our IPO for eight consecutive years and have achieved the EcoVadis Platinum rating for five consecutive years, placing Signify in the top one percent of companies assessed. News from Signify can be found in the Newsroom, on X, LinkedIn and Instagram. Information for investors is located on the Investor Relations page.
Irish Examiner
3 days ago
- Business
- Irish Examiner
Irish pig price holds firm as demand grows for home-reared stock
There was no change in Irish pig prices last Friday, with producers reporting an average of €2.28/kg for pigs sold in the Republic of Ireland. Some farmers reported prices up to 4c/kg above this, reflecting growing demand for ROI-born and reared pigs. The EU average price for week 23 for R-grade carcasses was 212c/kg excluding VAT — unchanged from the previous week but 2.6% higher than last month and 4% lower than the same month last year. Ireland's percentage of the EU average is currently 102%, based on figures reported to the EU Commission for the week commencing June 7. Factory pig throughput in ROI export plants for the week ending June 15 was 64,762 head — up 10,621 from the previous week and 1,197 more than the same week in 2024. Of this, 2,092 were sows. Oil prices increased due to Middle East tensions, and the euro has weakened against the dollar. Hot, dry weather in France is accelerating the barley harvest, though there are concerns about potential heat damage to wheat. On Euronext, grain and oilseed prices rose after a previous drop. Soyabean prices increased due to higher demand from the biofuel industry for soy oil. Read More The best way to utilise pig slurry on tillage land
Yahoo
3 days ago
- Business
- Yahoo
PHAXIAM Therapeutics Announces the Suspension of Trading in Its Shares Until Delisting
LYON, France, June 18, 2025--(BUSINESS WIRE)--Regulatory News: PHAXIAM Therapeutics (Euronext: PHXM - FR001400K4B1), hereinafter referred to as "the Company" or "PHAXIAM," a biopharmaceutical company specializing in the development of innovative treatments for resistant bacterial infections, asked Euronext to suspend trading of its shares listed on the Euronext Paris market starting today, Wednesday, June 18, 2025, before the market opens. Trading in PHAXIAM shares (FR001400K4B1) will remain suspended until the completion of the delisting procedure for PHAXIAM shares, which will take place shortly, following a request made to Euronext. As previously announced, no reimbursement will be made to shareholders. About PHAXIAM Therapeutics PHAXIAM is a biopharmaceutical company developing innovative treatments for resistant bacterial infections, which are responsible for many serious infections. The company is building on an innovative approach based on the use of phages, natural bacteria-killing viruses. PHAXIAM is developing a portfolio of phages targeting 3 of the most resistant and dangerous bacteria, which together account for more than two-thirds of resistant hospital-acquired infections: Staphylococcus aureus, Escherichia coli and Pseudomonas aeruginosa. PHAXIAM is listed on the Euronext regulated market in Paris (ISIN code: FR001400K4B1, ticker: PHXM). PHAXIAM is part of the CAC Healthcare, CAC Pharma & Bio, CAC Mid & Small, CAC All Tradable, EnterNext PEA-PME 150 and Next Biotech indexes. For more information, please visit View source version on Contacts PHAXIAM Thibaut du Fayet CEO+33 4 78 74 44 38investors@ NewCap Mathilde Bohin / Dušan Orešanský Investor RelationsArthur Rouillé Media Relations+33 1 44 71 94 94phaxiam@ Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Business Wire
3 days ago
- Business
- Business Wire
PHAXIAM Therapeutics Announces the Suspension of Trading in Its Shares Until Delisting
LYON, France--(BUSINESS WIRE)--Regulatory News: PHAXIAM Therapeutics (Euronext: PHXM - FR001400K4B1), hereinafter referred to as 'the Company' or 'PHAXIAM,' a biopharmaceutical company specializing in the development of innovative treatments for resistant bacterial infections, asked Euronext to suspend trading of its shares listed on the Euronext Paris market starting today, Wednesday, June 18, 2025, before the market opens. Trading in PHAXIAM shares (FR001400K4B1) will remain suspended until the completion of the delisting procedure for PHAXIAM shares, which will take place shortly, following a request made to Euronext. As previously announced, no reimbursement will be made to shareholders. About PHAXIAM Therapeutics PHAXIAM is a biopharmaceutical company developing innovative treatments for resistant bacterial infections, which are responsible for many serious infections. The company is building on an innovative approach based on the use of phages, natural bacteria-killing viruses. PHAXIAM is developing a portfolio of phages targeting 3 of the most resistant and dangerous bacteria, which together account for more than two-thirds of resistant hospital-acquired infections: Staphylococcus aureus, Escherichia coli and Pseudomonas aeruginosa. PHAXIAM is listed on the Euronext regulated market in Paris (ISIN code: FR001400K4B1, ticker: PHXM). PHAXIAM is part of the CAC Healthcare, CAC Pharma & Bio, CAC Mid & Small, CAC All Tradable, EnterNext PEA-PME 150 and Next Biotech indexes. For more information, please visit
